TY - JOUR T1 - Leflunomide and hypertension JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - 567 LP - 569 DO - 10.1136/ard.61.6.567 VL - 61 IS - 6 AU - B Rozman AU - S Praprotnik AU - D Logar AU - M Tomšič AU - M Hojnik AU - M Kos-Golja AU - R Accetto AU - P Dolenc Y1 - 2002/06/01 UR - http://ard.bmj.com/content/61/6/567.abstract N2 - Leflunomide is a new isoxazole drug with disease modifying properties for the treatment of rheumatoid arthritis (RA). Hypertension has been mentioned as a common side effect of the treatment. It was found in up to 10.6% of patients receiving 25 mg leflunomide in a phase II study.1 New onset hypertension occurred in 3.7% of patients in a phase III European study,2 and in 2.1% of patients, with a mean increase in systolic and diastolic blood pressure of 2.2 and 1.9 mm Hg, respectively, in an American phase III study.3 There was no evidence that hypertension was related to an impairment of renal function or proteinuria. The changes in blood pressure during leflunomide treatment have not been studied in detail. Thirty consecutive patients fulfilling the American Rheumatism Association criteria for RA were recruited into a prospective study and treated with standard doses of leflunomide. Other enrolment criteria included stable treatment with non-steroidal anti-inflammatory drugs up to the maximum recommended dose and/or corticosteroid treatment … ER -